JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful functional improvements.
A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to increase bets on a more significant 50
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle strength, and dystrophin expression were observed.
